Mid-Afternoon Market Update: Nasdaq Tumbles 150 Points; Knoll Shares Spike Higher benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
NVAX s Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial
Read on.
1. Will Ayala Pharma s Tenacity Pay Off?
Ayala Pharmaceuticals Inc. (AYLA) has dosed the first patient in its phase II clinical trial of AL101 for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer.
The trial, dubbed TENACITY, is expected to initially enroll up to 26 patients with Notch-activated R/M TNBC whose disease has recurred or progressed after three or fewer lines of prior therapy. The preliminary data from the trial is expected to be reported by the end of 2021.
NantKwest Stock Goes North, uniQure s HOPE-B Trial On Hold, EU Greenlights First COVID-19 Vaccine
NEW YORK CITY (dpa-AFX) - Today s Daily Dose brings you news about NantKwest s non-muscle invasive bladder cancer trial results and the company s proposed merger with privately-held ImmunityBio; Agios sale of oncology portfolio to Servier for $1.8 billion upfront; the clinical hold on uniQure s hemophilia B gene therapy program due to safety concerns; ChemoCentryx ACCOLADE trial results; and the first COVID-19 vaccine authorized in the EU.
Read on.
1. Agios Sells Oncology Portfolio for $1.8 Bln Upfront
Agios Pharmaceuticals Inc. (AGIO) is all set to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company, for up to $2.0 billion in cash.